Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pharmather Hldgs Ltd (PHRRF)

Pharmather Hldgs Ltd (PHRRF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade PHRRF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1000 +2.60%
on 05/18/22
0.1668 -38.49%
on 04/27/22
-0.0074 (-6.73%)
since 04/20/22
3-Month
0.0825 +24.36%
on 04/07/22
0.2180 -52.94%
on 03/21/22
-0.0975 (-48.73%)
since 02/18/22
52-Week
0.0825 +24.36%
on 04/07/22
0.9888 -89.62%
on 07/26/21
-0.1741 (-62.92%)
since 05/20/21

Most Recent Stories

More News
PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion product,...

PHRM.CN : 0.130 (unch)
PHRRF : 0.1026 (-0.29%)
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs

PharmaTher to file ANDA and 505(b)(2) regulatory submissions with the FDA for novel uses, delivery forms and formulations of ketamine for mental health,...

PHRRF : 0.1026 (-0.29%)
PHRM.CN : 0.130 (unch)
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease

100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was well...

PHRM.CN : 0.130 (unch)
PHRRF : 0.1026 (-0.29%)
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

TORONTO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty...

PHRRF : 0.1026 (-0.29%)
PHRM.CN : 0.130 (unch)
PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus

Third FDA orphan drug designation for ketamine granted to PharmaTher...

PHRRF : 0.1026 (-0.29%)
PHRM.CN : 0.130 (unch)
PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the...

PHRRF : 0.1026 (-0.29%)
PHRM.CN : 0.130 (unch)
PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022

Focused on becoming a leader in the development and commercialization of specialty ketamine prescription-based products Expected milestones for 2022...

PHRM.CN : 0.130 (unch)
PHRRF : 0.1026 (-0.29%)
PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio

TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage...

PHRRF : 0.1026 (-0.29%)
PHRM.CN : 0.130 (unch)
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus

Adds to PharmaTher’s existing FDA orphan drug portfolio with amyotrophic lateral sclerosis and complex regional pain syndromeStrengthens commitment to...

PHRRF : 0.1026 (-0.29%)
PHRM.CN : 0.130 (unch)
PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

Delivering psilocybin via microneedle patch unlocks potential for desired dosage forms and pharmacokinetic profiles for improved safety and...

PHRRF : 0.1026 (-0.29%)
PHRM.CN : 0.130 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 0.1099
2nd Resistance Point 0.1078
1st Resistance Point 0.1052
Last Price 0.1026
1st Support Level 0.1005
2nd Support Level 0.0984
3rd Support Level 0.0958

See More

52-Week High 0.9888
Fibonacci 61.8% 0.6426
Fibonacci 50% 0.5357
Fibonacci 38.2% 0.4287
Last Price 0.1026
52-Week Low 0.0825

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar